Kyverna Therapeutics, Inc. (KYTX)
$6.39+3.40%Close
SELLCRISIS · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $388M
- Beta
- 2.06
- P/E (TTM)
- -2.10
- Short % float
- 34.94%
- Days to cover
- 8.8
- SI change
- +9.7%
- 1W
- +2.73%
- 1M
- -13.06%
- vs SPY 1W
- +1.57%
- vs SPY 1M
- -16.05%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on KYTX?
- LOPJLB’s latest quantitative signal on Kyverna Therapeutics, Inc. (KYTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is KYTX in?
- Kyverna Therapeutics, Inc. (KYTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Kyverna Therapeutics, Inc. (KYTX) do?
- Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also deve…